CareDx has developed AlloSeq cfDNA, a targeted NGS assay that relies on 202 single-nucleotide polymorphisms (SNPs) located throughout the genome to measure the dd-cfDNA in transplant recipients. The assay was designed to be fully compatible with any clinical laboratory setup and combines a streamlined workflow with a fully automated analysis software to accurately quantify dd-cfDNA in transplant recipients.
CareDx’s AlloSeq cfDNA Represents a Minimally Invasive, Accurate Method to Detect Graft Injury as a Leading Solution for Transplant Patient Management in Europe
